$294.55
Value $521B
ABBV and DXCM stock compared: price, dividend, valuation and results, from SEC filings.
$294.55
Value $521B
$81.61
Value $31.4B
AbbVie (ABBV) has a market value of $521B and DexCom (DXCM) $31.4B. Over the last year, with dividends, ABBV moved +30.3% and DXCM +39.8%. The P/E is 50.6 for ABBV and 31.7 for DXCM. Dividend yield: ABBV 2.35%, DXCM none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABBV$521B
DXCM$31.4B
ABBV is 17 times DXCM
Revenue, 12 months
ABBV$66.0B
DXCM$5.1B
ABBV is 13 times DXCM
Net income, 12 months
ABBV$10.3B
DXCM$991M
ABBV is 10 times DXCM
Operating margin
ABBV32.2%
DXCM24.0%
8.2 points apart
ROIC
ABBV25.7%
DXCM19.5%
6.2 points apart
P/E
ABBV50.6
DXCM31.7
ABBV is 1.6 times DXCM
Dividend yield
ABBV2.4%
DXCM0.0%
2.4 points apart
5-year return
ABBV+201.5%
DXCM-48.4%
249.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABBV+201.5%
DXCM-48.4%
| Period | ABBVWith dividends | DXCMWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +30.3%Price +26.5% | +39.8%Price +39.8% |
| 3 years since November 13, 2023 | +135.3%+33.0% a yearPrice +112.8% | -15.3%-5.4% a yearPrice -15.3% |
| 5 years since November 12, 2021 | +201.5%+24.7% a yearPrice +152.2% | -48.4%-12.4% a yearPrice -48.4% |
| 10 years since November 16, 2016 | +620.7%+21.8% a yearPrice +379.4% | +367.6%+16.7% a yearPrice +367.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABBVAbbVieDXCMDexCom
| Price | $294.55 | $81.61 |
|---|---|---|
| Market value | $521B | $31.4B |
| Enterprise value (EV) | $591B | $31.0B |
| P/E | 50.6 | 31.7 |
| P/E, 5-year median | 57.0 | 54.8 |
| P/B | – | 12.4 |
| EV/EBIT | 27.8 | 25.4 |
| Free cash flow yield | 3.6% | 3.5% |
| Revenue, 12 months | $66.0B | $5.1B |
|---|---|---|
| Net income, 12 months | $10.3B | $991M |
| Free cash flow, 12 months | $18.9B | $1.1B |
| Earnings per share, 12 months | $5.81 | $2.54 |
| Revenue growth, year on year | 8.6% | 15.6% |
| Revenue growth a year, past | +5.9%over 5 years | +19.3%over 5 years |
| EPS growth a year, past | -2.8%over 5 years | +44.4%over 5 years |
| Gross margin | 73.7% | 63.4% |
|---|---|---|
| Operating margin | 32.2% | 24.0% |
| Net margin | 15.7% | 19.4% |
| ROIC | 25.7% | 19.5% |
| ROE | – | 36.5% |
| Cash | $10.8B | $1.7B |
|---|---|---|
| Total debt | $80.9B | $1.4B |
| Net debt / EBITDA | 3.2 | -0.3 |
| Interest cover | 7.1× | 128.8× |
| Dividend yield | 2.4% | – |
|---|---|---|
| Dividend per share, 12 months | $6.92 | – |
| Dividend growth a year, past | +6.6%over 5 years | – |
| Buyback yield | 0.2% | 1.6% |
| Shareholder yield | 2.5% | 1.6% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, AbbVie ($521B) is about 16.6 times DexCom ($31.4B), at today's prices.
Since November 16, 2016, ABBV's price moved +379.4% and DXCM's +367.6%. With dividends: ABBV +620.7% (+21.8% a year), DXCM +367.6% (+16.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.35% for AbbVie and none for DexCom. Over the last twelve months they paid $6.92 and – per share.
At today's price, the P/E is 50.6 for ABBV and 31.7 for DXCM. The median of the last five years was 57.0 and 54.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 15.7% for AbbVie and 19.4% for DexCom, and the operating margin 32.2% and 24.0%. Revenue was $66.0B and $5.1B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.